- Home
- LX vs NRXP Comparison
LX vs NRXP Comparison
Compare LX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LX | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 151.1M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LX | NRXP |
|---|---|---|
| Price | $0.61 | $2.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $2.13 | ★ $38.75 |
| AVG Volume (30 Days) | 918.2K | ★ 1.3M |
| Earning Date | 11-27-2026 | 11-17-2026 |
| Dividend Yield | ★ 64.50% | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $357.94 |
| Revenue Next Year | N/A | $1,281.36 |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $1.65 |
| 52 Week High | $4.13 | $5.06 |
Technical Indicators
Market Signals| Indicator | LX | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 37.96 |
| Support Level | $0.60 | $1.70 |
| Resistance Level | $0.74 | $2.23 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 10.88 | 15.75 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.